We work across four areas:

Steering Committee

Our Patient Charter

The Global Lung Cancer Coalition Patient Charter is an affirmation by all the member organisations of the basic rights that all lung cancer patients should be granted.

We, the Global Lung Cancer Coalition, hereby adopt this charter and call upon its observance by all concerned on behalf of the 2.21 million people diagnosed with lung cancer around the world and the countless millions more at risk of the disease.

• Recognising that lung cancer is the leading cause of cancer death in both men and women world-wide; consistently it will kill more people than breast, prostate, and colon cancer combined. Only 4 in 10 lung cancer sufferers today can expect to survive for more than one year, the worst rate amongst all the major types of cancer
• Aware of the fact that funding for lung cancer research falls far short of that for other less fatal diseases. Lack of investment in research has left lung cancer patients with few treatment options and many patients do not receive the best treatment available
• Acknowledging that most lung cancers are discovered when the disease is far advanced and, in many countries, there is currently no approved screening for lung cancer, which would detect smaller, and more curable tumours
• Troubled by lung cancer patients’ isolation, the uphill struggle they face in fighting for their rights and their frequent unwillingness to seek treatment promptly because of the stigma associated with a tobacco-related disease and recognising how negative attitudes about lung cancer held by some professional carers, policymakers, and the public compound this situation

The Rights of People with Lung Cancer

In addition to the right of every patient to be treated with dignity and respect, the Global Lung Cancer Coalition reaffirms the right of all lung cancer patients to have access to quality health care; informed self-determination; physical and mental integrity; and confidentiality and privacy.

Along with these fundamental rights, lung cancer patients have the right to:

• help to give up smoking, if a smoker, and not to be denied treatment or support if they are unable to overcome their addiction.
• have the enormous burden of lung cancer acknowledged by professional carers, policy makers and the public
• have access to optimal treatment as suggested by a multi-disciplinary team of medical professionals, who should possess specialist knowledge about lung cancer
• have their voice heard in corridors of power as evidenced by the allocation of an equitable portion of available funds to lung cancer research and treatment
• witness the widespread implementation of well structured, evidence-based programs of early diagnosis and timely medical referral
• be free of blame and stigma for having the disease and to have their disease de-stigmatised

Our strength

The Coalition’s impact comes from its members. By uniting organisations with deep local knowledge and global reach, we amplify expertise, share the best available information, and create change that no single organisation could achieve alone.

[MEMBER LIST]

The Lung Ambition Alliance

The Lung Ambition Alliance (LAA) is a partnership of four organisations united by a single goal: eliminating lung cancer as a cause of death. Founded by IASLC, Guardant Health, the Global Lung Cancer Coalition (GLCC), and AstraZeneca, the Alliance combines expertise across research, diagnostics, patient advocacy, and medicines development to accelerate progress for patients.

Its work focuses on three priorities: increasing screening and early diagnosis, delivering innovative treatments, and improving quality of care.

“The Lung Ambition Alliance has been created at a pivotal time for lung cancer. Scientific advances are enabling new possibilities to transform diagnosis, treatment and the management of the disease. Yet barriers remain. As members of the lung cancer community, we have a responsibility to come together with urgency to advocate for and advance the best solutions for patients.”

— Jesme Fox, Secretary, GLCC

Current projects

The Alliance has also published Lung Cancer Screening: The Cost of Inaction, highlighting the economic burden of late diagnosis and the case for investment in targeted screening programmes. [Read more →]

Teravolt

The global TERAVOLT registry, initiated in March 2020, aims to provide outcome data specific to patients with thoracic cancer, who contracted COVID-w19. The data collected will, hopefully, guide disease management and define factors influencing associated morbidity and mortality. The Lung Ambition Alliance has recently announced that it is providing new funding for TERAVOLT.

Awards

The global awards for excellence in journalism recognise excellence in raising awareness of the world’s biggest cancer killer. The awards were launched in 2011 and continue to this day. Each member organisation is encouraged to nominate a recipient.

In recent years we have expanded the definition of ‘journalism’ to reflect the way that social media and digital platforms are rapidly covering much of the ground previously occupied by mainstream media, such as press, radio and television.

We also recognise that ‘’citizen journalists’ are playing an important role in the way information is shared, and that the outstanding efforts of individuals or groups not part of the mainstream media can often produce outstandingly effective work that significantly raises awareness of lung cancer and matters surrounding it. These efforts too can be recognised with an award; often, in such circumstances, members choose to make a ‘Special Award’ for outstanding contributions.

• Journalism & Special Recognition Awards 2025
• Journalism & Special Recognition Awards 2024
• Journalism Awards 2023
• Journalism & Special Recognition Awards 2021/22
• Journalism Awards 2018
• Journalism Awards 2017
• Etc

News